Literature DB >> 1446003

Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide.

J R Cashman1, S B Park, Z C Yang, S A Wrighton, P Jacob, N L Benowitz.   

Abstract

Liver microsomes from humans catalyze the NADPH-dependent oxidation of (S)-nicotine. The principal product is the 5'-carbon atom oxidation product, nicotine delta 1',5'-iminium ion, which is efficiently converted to the gamma-lactam derivative cotinine in the presence of aldehyde oxidase. Another major product is nicotine N'-oxide. In contrast to previous reports describing in vitro or in vivo studies, formation of only trans-nicotine N'-oxide was observed. Demethylation of nicotine was not observed. Studies on the biochemical mechanism of nicotine 5-carbon atom oxidation strongly implicate one major cytochrome P-450 isoenzyme (i.e., P-450 2A6) as largely responsible for delta 1',5'-iminium ion formation. Stereoselective formation of trans-nicotine N'-oxide may be catalyzed in large part by the flavin-containing monooxygenase (form II). These conclusions are based on the effects of alternate substrates for the flavin-containing monooxygenase, heat inactivation studies, immunoblot studies, and selective substrates for cytochromes P-450. The results suggest that (S)-nicotine trans N'-oxygenation and delta 1',5'-iminium ion formation may be selective probes of human liver flavin-containing monooxygenase form II and cytochrome P-450 2A6 activities, respectively, useful for in vivo phenotyping of humans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446003     DOI: 10.1021/tx00029a008

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  34 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Effect of pregnancy on a measure of FMO3 activity.

Authors:  Janne Hukkanen; Delia Dempsey; Peyton Jacob; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

3.  A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.

Authors:  Man Ki Ho; Jill C Mwenifumbo; Bin Zhao; Elizabeth M J Gillam; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

4.  Applications of CYP-450 expression for biomonitoring in environmental health.

Authors:  Ho-Sun Lee; Mihi Yang
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

5.  Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry.

Authors:  Michael G Feasel; Ariane Wohlfarth; John M Nilles; Shaokun Pang; Robert L Kristovich; Marilyn A Huestis
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

6.  Substituted heteroaromatic compounds: effect on nicotine self-administration in rats.

Authors:  John R Cashman; Karl Okolotowicz; Matt Cerny; Robert Johnson; Aaron Janowsky; Marc R Azar
Journal:  Psychopharmacology (Berl)       Date:  2012-01-05       Impact factor: 4.530

7.  Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine.

Authors:  Dongmei Li; Yong Wang; Keli Han; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-07-15       Impact factor: 2.991

Review 8.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

Review 9.  Nicotine chemistry, metabolism, kinetics and biomarkers.

Authors:  Neal L Benowitz; Janne Hukkanen; Peyton Jacob
Journal:  Handb Exp Pharmacol       Date:  2009

10.  Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model.

Authors:  Xin Zhou; Xiaoliang Zhuo; Fang Xie; Kerri Kluetzman; Yue-Zhong Shu; W Griffith Humphreys; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2009-11-18       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.